Anavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016
This should be double digits, Eihorn will get us there or sell shares for $20 per share and make us all a ton of money
Small cap stock picking:, Anavex Life Sciences Corp. (NASDAQ:AVXL)
Small cap stock picking: Anavex Life Sciences Corp. (NASDAQ:AVXL),
By Michael Welch • December 18, 2015
Dr. Elben will oversee the pipeline development and optimization.
“What attracted me to join Anavex is the very impressive pipeline consisting of potential breakthrough therapies for indications with very high unmet medical need like Alzheimer’s disease and other indications having potential beneficial impact on patients’ lives,” said Ulrich Elben, PhD.
“We are pleased to welcome Dr. Elben to Anavex during this exciting time in our growth. He has bothexperience and a shared passion for bringing promising drug candidates through the development cycle to market in an effort to serve patients with devastating diseases,” said Dr. Christopher U. Missling, PhD, President and Chief Executive Officer for Anavex. “His expertise in the management of multidisciplinary programs is expected to add valuable depth to our team.”
at this price and shares will be $20+
Scientific Journal is renowned publication. Leerink has also said the data was excellent.
Best biotech on Wall Street.
Sentiment: Strong Buy
The Fly On The Wall
Breaking News feed
Clovis Oncology, Inc. - Ir
The following excerpt is from the company's SEC filing.
As the efficacy data had matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected. In the intent-to-treat analysis of the 79 patients in the 500 milligrams dose group, the current confirmed response rate is 28% and in the 170 patients in the 625
milligram dose group, its 34%. In both cases we have a duration of response of nine months.
feel bad for folks who are buying. This is the guy that killed biotech he charged $700 for a $13 pill